How should patients who decline maintenance therapy be managed?

Management of Patients Who Decline Maintenance Therapy

Patients who decline maintenance therapy after achieving remission should be closely monitored with regular clinical assessments and objective markers of disease activity, with prompt re-initiation of treatment at first signs of relapse, as re-treatment is generally successful though outcomes may vary by disease type.

Disease-Specific Approaches

Multiple Myeloma

For patients with multiple myeloma who decline maintenance therapy after achieving deep response or plateau, the evidence suggests several key considerations 1:

• Re-treatment at relapse is feasible: When these patients eventually relapse after discontinuing therapy, they can be effectively treated with combination regimens
• Fit patients: Should receive carfilzomib, lenalidomide, and dexamethasone (KRd), which demonstrated superior progression-free survival (26.3 vs 17.6 months) compared to lenalidomide-dexamethasone alone 1
• Frail patients: Should be treated with ixazomib-based (IRd) or daratumumab-based regimens 1

The critical caveat: While re-treatment is usually successful, patients should be counseled that declining maintenance increases relapse risk. In multiple myeloma specifically, maintenance lenalidomide is strongly recommended for standard-risk patients for at least 2 years, as it improves survival 2. However, recent data suggest that patients with sustained MRD negativity for ≥12 months may potentially discontinue maintenance after 3 years, particularly in standard-risk disease 3.

Inflammatory Bowel Disease (Crohn's Disease)

For Crohn's disease patients declining anti-TNF maintenance 4:

• High relapse risk: Even with ≥6 months of corticosteroid-free clinical, biochemical, and endoscopic remission, anti-TNF withdrawal carries approximately one-in-three risk of relapse within 1-2 years
• Monitoring strategy: Use clinical symptoms plus objective markers (C-reactive protein, fecal calprotectin) and/or endoscopy/non-invasive imaging
• Re-treatment: Usually successful, though treatment failure rates may be higher in smokers

ANCA-Associated Vasculitis

The vasculitis guidelines provide clear direction 5:

• Duration considerations: Maintenance therapy typically continues for ≥18 months, potentially longer based on relapse history, organ involvement, and ANCA status (PR3-ANCA-positive patients have higher relapse risk)
• Patient preference matters: Duration should be guided by clinical condition and patient values
• No maintenance for specific subgroups: Patients who are dialysis-dependent without extrarenal manifestations should not receive maintenance therapy 6

Universal Monitoring Principles

Regardless of disease type, patients declining maintenance require:

1. Baseline confirmation of remission using clinical, biochemical, endoscopic/histological, and/or radiological assessments before stopping therapy
2. Regular monitoring schedule (typically every 3 months minimum) with disease-specific markers
3. Clear relapse criteria established upfront
4. Rapid access to re-treatment when relapse occurs

Common Pitfalls to Avoid

• Assuming all patients need indefinite maintenance: Some disease states and patient subgroups may not benefit from prolonged therapy
• Inadequate monitoring after discontinuation: Patients who decline maintenance are not "lost to follow-up" candidates—they require structured surveillance
• Delayed re-treatment: Once relapse is detected, prompt intervention is critical as outcomes worsen with treatment delays
• Ignoring patient-specific factors: Smoking status (Crohn's), ANCA type (vasculitis), cytogenetic risk (myeloma), and prior relapse history all influence relapse risk and should inform shared decision-making

Shared Decision-Making Framework

When patients decline maintenance, document discussion of:

• Quantified relapse risk specific to their disease and risk factors
• Consequences of relapse (hospitalization, organ damage, treatment complexity)
• Re-treatment success rates and potential limitations
• Monitoring plan with specific intervals and tests
• Triggers for re-initiating treatment

The decision should balance the patient's quality of life concerns about ongoing treatment against the measurable increased risk of disease recurrence, with clear understanding that while re-treatment is often effective, preventing relapse is generally preferable to treating it.